Cargando…

Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis

BACKGROUND: Timely diagnosis and treatment of hepatitis C virus (HCV) is critical to achieve elimination goals. This study evaluated the cost-effectiveness of point-of-care testing strategies for HCV compared to laboratory-based testing in standard-of-care. METHODS: Cost-effectiveness analyses were...

Descripción completa

Detalles Bibliográficos
Autores principales: Shih, Sophy T.F., Cheng, Qinglu, Carson, Joanne, Valerio, Heather, Sheehan, Yumi, Gray, Richard T., Cunningham, Evan B., Kwon, Jisoo A., Lloyd, Andrew R., Dore, Gregory J., Wiseman, Virginia, Grebely, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398594/
https://www.ncbi.nlm.nih.gov/pubmed/37547040
http://dx.doi.org/10.1016/j.lanwpc.2023.100750
_version_ 1785084086337929216
author Shih, Sophy T.F.
Cheng, Qinglu
Carson, Joanne
Valerio, Heather
Sheehan, Yumi
Gray, Richard T.
Cunningham, Evan B.
Kwon, Jisoo A.
Lloyd, Andrew R.
Dore, Gregory J.
Wiseman, Virginia
Grebely, Jason
author_facet Shih, Sophy T.F.
Cheng, Qinglu
Carson, Joanne
Valerio, Heather
Sheehan, Yumi
Gray, Richard T.
Cunningham, Evan B.
Kwon, Jisoo A.
Lloyd, Andrew R.
Dore, Gregory J.
Wiseman, Virginia
Grebely, Jason
author_sort Shih, Sophy T.F.
collection PubMed
description BACKGROUND: Timely diagnosis and treatment of hepatitis C virus (HCV) is critical to achieve elimination goals. This study evaluated the cost-effectiveness of point-of-care testing strategies for HCV compared to laboratory-based testing in standard-of-care. METHODS: Cost-effectiveness analyses were undertaken from the perspective of Australian Governments as funders by modelling point-of-care testing strategies compared to standard-of-care in needle and syringe programs, drug treatment clinics, and prisons. Point-of-care testing strategies included immediate point-of-care HCV RNA testing and combined point-of-care HCV antibody and reflex RNA testing for HCV antibody positive people (with and without consideration of previous treatment). Sensitivity analyses were performed to investigate the cost per treatment initiation with different testing strategies at different HCV antibody prevalence levels. FINDINGS: The average costs per HCV treatment initiation by point-of-care testing, from A$890 to A$1406, were up to 35% lower compared to standard-of-care ranging from A$1248 to A$1632 depending on settings. The average costs per treatment initiation by point-of-care testing for three settings ranged from A$1080 to A$1406 for RNA, A$960–A$1310 for combined antibody/RNA without treatment history consideration, and A$890–A$1189 for combined antibody/RNA with treatment history consideration. When HCV antibody prevalence was <74%, combined point-of-care HCV antibody and point-of-care RNA testing were the most cost-effective strategies. Modest increases in treatment uptake by 8%–31% were required for immediate point-of-care HCV RNA testing to achieve equivalent cost per treatment initiation compared to standard-of-care. INTERPRETATION: Point-of-care testing is more cost-effective than standard of care for populations at risk of HCV. Testing strategies combining point-of-care HCV antibody and RNA testing are likely to be cost-effective in most settings. FUNDING: 10.13039/501100000925National Health and Medical Research Council.
format Online
Article
Text
id pubmed-10398594
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103985942023-08-04 Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis Shih, Sophy T.F. Cheng, Qinglu Carson, Joanne Valerio, Heather Sheehan, Yumi Gray, Richard T. Cunningham, Evan B. Kwon, Jisoo A. Lloyd, Andrew R. Dore, Gregory J. Wiseman, Virginia Grebely, Jason Lancet Reg Health West Pac Articles BACKGROUND: Timely diagnosis and treatment of hepatitis C virus (HCV) is critical to achieve elimination goals. This study evaluated the cost-effectiveness of point-of-care testing strategies for HCV compared to laboratory-based testing in standard-of-care. METHODS: Cost-effectiveness analyses were undertaken from the perspective of Australian Governments as funders by modelling point-of-care testing strategies compared to standard-of-care in needle and syringe programs, drug treatment clinics, and prisons. Point-of-care testing strategies included immediate point-of-care HCV RNA testing and combined point-of-care HCV antibody and reflex RNA testing for HCV antibody positive people (with and without consideration of previous treatment). Sensitivity analyses were performed to investigate the cost per treatment initiation with different testing strategies at different HCV antibody prevalence levels. FINDINGS: The average costs per HCV treatment initiation by point-of-care testing, from A$890 to A$1406, were up to 35% lower compared to standard-of-care ranging from A$1248 to A$1632 depending on settings. The average costs per treatment initiation by point-of-care testing for three settings ranged from A$1080 to A$1406 for RNA, A$960–A$1310 for combined antibody/RNA without treatment history consideration, and A$890–A$1189 for combined antibody/RNA with treatment history consideration. When HCV antibody prevalence was <74%, combined point-of-care HCV antibody and point-of-care RNA testing were the most cost-effective strategies. Modest increases in treatment uptake by 8%–31% were required for immediate point-of-care HCV RNA testing to achieve equivalent cost per treatment initiation compared to standard-of-care. INTERPRETATION: Point-of-care testing is more cost-effective than standard of care for populations at risk of HCV. Testing strategies combining point-of-care HCV antibody and RNA testing are likely to be cost-effective in most settings. FUNDING: 10.13039/501100000925National Health and Medical Research Council. Elsevier 2023-04-04 /pmc/articles/PMC10398594/ /pubmed/37547040 http://dx.doi.org/10.1016/j.lanwpc.2023.100750 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Shih, Sophy T.F.
Cheng, Qinglu
Carson, Joanne
Valerio, Heather
Sheehan, Yumi
Gray, Richard T.
Cunningham, Evan B.
Kwon, Jisoo A.
Lloyd, Andrew R.
Dore, Gregory J.
Wiseman, Virginia
Grebely, Jason
Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis
title Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis
title_full Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis
title_fullStr Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis
title_full_unstemmed Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis
title_short Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis
title_sort optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis c virus infection in australia: a model-based cost-effectiveness analysis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398594/
https://www.ncbi.nlm.nih.gov/pubmed/37547040
http://dx.doi.org/10.1016/j.lanwpc.2023.100750
work_keys_str_mv AT shihsophytf optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT chengqinglu optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT carsonjoanne optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT valerioheather optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT sheehanyumi optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT grayrichardt optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT cunninghamevanb optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT kwonjisooa optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT lloydandrewr optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT doregregoryj optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT wisemanvirginia optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis
AT grebelyjason optimizingpointofcaretestingstrategiesfordiagnosisandtreatmentofhepatitiscvirusinfectioninaustraliaamodelbasedcosteffectivenessanalysis